Literature DB >> 29975928

A Preliminary Investigation of PVT1 on the Effect and Mechanisms of Hepatocellular Carcinoma: Evidence from Clinical Data, a Meta-Analysis of 840 Cases, and In Vivo Validation.

Yu Zhang1, Dong-Yue Wen2, Rui Zhang1, Jia-Cheng Huang1, Peng Lin2, Fang-Hui Ren1, Xiao Wang3, Yun He2, Hong Yang2, Gang Chen1, Dian-Zhong Luo1.   

Abstract

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) remains a difficult problem that significantly affects the survival of the afflicted patients. Accumulating evidence has demonstrated the functions of long non-coding RNA (lncRNA) in HCC. In the present study, we aimed to explore the potential roles of PVT1 in the tumorigenesis and progression of HCC.
METHODS: In this study, quantitative reverse transcription-polymerase chain reaction (RT-qPCR) was applied to detect the differences between PVT1 expression in HCC tissues and cell lines. Then, the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were searched to confirm the relationship between PVT1 expression and HCC. Moreover, a meta-analysis comprising TCGA, GEO, and RT-qPCR was applied to estimate the expression of PVT1 in HCC. Then, cell proliferation was evaluated in vitro. A chicken chorioallantoic membrane (CAM) model of HCC was constructed to measure the effect on tumorigenicity in vivo. To further explore the sponge microRNA (miRNA) of PVT1 in HCC, we used TCGA, GEO, a gene microarray, and target prediction algorithms. TCGA and GEO and the gene microarray were used to select the differentially expressed miRNAs, and the different target prediction algorithms were applied to predict the target miRNAs of PVT1.
RESULTS: We found that PVT1 was markedly overexpressed in HCC tissue than in normal liver tissues based on both RT-qPCR and data from TCGA, and the overexpression of PVT1 was closely related to the gender and race of the patient as well as to higher HCC tumor grades. Also, a meta-analysis of 840 cases from multiple sources (TCGA, GEO and the results of our in-house RT-qPCR) showed that PVT1 gained moderate value in discriminating HCC patients from normal controls, confirming the results of RT-qPCR. Additionally, the upregulation of PVT1 could promote HCC cell proliferation in vitro and vivo. Based on the competing endogenous RNA (ceRNA) theory, the PVT1/miR-424-5p/INCENP axis was finally selected for further research. The in silico prediction revealed that there were complementary sequences between PVT1 and miR-424-5p as well as between miR-424-5p and INCENP. Furthermore, a negative correlation trend was found between miR-424-5p and PVT1 based on RT-qPCR, whereas a positive correlation trend was found between PVT1 and INCENP based on data from TCGA. Also, INCENP small interfering RNA (siRNA) could significantly inhibit cell proliferation and viability.
CONCLUSIONS: We hypothesized that PVT1 could affect the biological function of HCC cells via targeting miR-424-5p and regulating INCENP. Focusing on the new insight of the PVT1/miR-424-5p/INCENP axis, this study provides a novel perspective for HCC therapeutic strategies.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  CAM; GEO; Hepatocellular carcinoma; INCENP; MiR-424-5p; Pvt1; TCGA

Mesh:

Substances:

Year:  2018        PMID: 29975928     DOI: 10.1159/000491534

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  13 in total

Review 1.  PVT1 Signaling Is a Mediator of Cancer Progression.

Authors:  Camille Derderian; Akintunde T Orunmuyi; E Oluwabunmi Olapade-Olaopa; Olorunseun O Ogunwobi
Journal:  Front Oncol       Date:  2019-06-12       Impact factor: 6.244

2.  Comprehensive investigation of the clinical significance and molecular mechanisms of plasmacytoma variant translocation 1 in sarcoma using genome-wide RNA sequencing data.

Authors:  Jianwei Liu; Rong Li; Xiwen Liao; Bangli Hu; Jia Yu
Journal:  J Cancer       Date:  2019-08-27       Impact factor: 4.207

3.  The prognostic value of long noncoding RNA SNHG16 on clinical outcomes in human cancers: a systematic review and meta-analysis.

Authors:  Chenghao Zhang; Xiaolei Ren; Jieyu He; Wanchun Wang; Chao Tu; Zhihong Li
Journal:  Cancer Cell Int       Date:  2019-10-11       Impact factor: 5.722

Review 4.  Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis.

Authors:  Ke Jin; Shufei Wang; Yazhuo Zhang; Mengfang Xia; Yongzhen Mo; Xiaoling Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong; Yi He
Journal:  Cell Mol Life Sci       Date:  2019-07-15       Impact factor: 9.261

Review 5.  Sequence Requirements for miR-424-5p Regulating and Function in Cancers.

Authors:  Jiangying Xuan; Yingxia Liu; Xiaoping Zeng; Hongmei Wang
Journal:  Int J Mol Sci       Date:  2022-04-06       Impact factor: 5.923

6.  Identification of ceRNA network based on a RNA-seq shows prognostic lncRNA biomarkers in human lung adenocarcinoma.

Authors:  Xing Li; Bing Li; Pixin Ran; Lanying Wang
Journal:  Oncol Lett       Date:  2018-08-21       Impact factor: 2.967

Review 7.  Chemoresistance Mediated by ceRNA Networks Associated With the PVT1 Locus.

Authors:  Olorunseun O Ogunwobi; Adithya Kumar
Journal:  Front Oncol       Date:  2019-08-27       Impact factor: 6.244

Review 8.  Regulatory Mechanisms and Clinical Applications of the Long Non-coding RNA PVT1 in Cancer Treatment.

Authors:  Meng-Yuan Li; Xiao-Huan Tang; Yan Fu; Tie-Jun Wang; Jia-Ming Zhu
Journal:  Front Oncol       Date:  2019-08-21       Impact factor: 6.244

9.  Prognostic value and prospective molecular mechanism of miR-100-5p in hepatocellular carcinoma: A comprehensive study based on 1,258 samples.

Authors:  Qing-Lin He; Shan-Yu Qin; Lin Tao; Hong-Jian Ning; Hai-Xing Jiang
Journal:  Oncol Lett       Date:  2019-10-04       Impact factor: 2.967

10.  Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma.

Authors:  Yong-Fa Zhang; Yi-Xiu Wang; Ning- Zhang; Zhen-Hai Lin; Long-Rong Wang; Yun Feng; Qi Pan; Lu Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.